Anuj Verma - Concepedia

Author

Anuj Verma

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

A K Verma, A. Verma, Anuj Verma, Munita Bal, Santosh Menon

Publications

551

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Homi Bhabha National Institute Tata Memorial Hospital

About

Anuj Verma is an author at The University of Texas MD Anderson Cancer Center specializing in cancer research, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	25
2	Pathology	2	2	25
3	Pharmacology	1	1	12
4	Cancer Cell Biology	1	1	12
5	Cancer Therapeutics	1	1	12

Anuj Verma

Publications

329

Citations

H-Index

Page 1

	Year	Citations
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma Kanwal Raghav, Suyu Liu, Michael J. Overman, Cancer Discovery	2021	71
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC Aliya Qayyum, Ken‐Pin Hwang, Jason Stafford, Journal for ImmunoTherapy of Cancer	2019	50
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Amir Mehrvarz Sarshekeh, Jumanah Alshenaifi, Jason Roszik, Clinical Cancer Research	2021	49
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) Benny Johnson, Cara Haymaker, Edwin R. Parra, Journal for ImmunoTherapy of Cancer	2022	48
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors Daniel M. Halperin, Suyu Liu, Arvind Dasari, JAMA Oncology	2022	36
Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma Zhimin Tong, Alicia Mejia, Omkara Veeranki, Therapeutic Advances in Medical Oncology	2019	15
Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance Akash Sali, Nishtha Sharma, Anuj Verma, Clinical Breast Cancer Breast OncologyOncologyLuminal SubtypesMedicinePathology	2020	13
Phase I/II trial of the MEK1/2 inhibitor GSK1120212 (GSK212) in patients (pts) with relapsed/refractory myeloid malignancies: Evidence of activity in pts with RAS mutation. Gautam Borthakur, Leslie Popplewell, Mark Kirschbaum, Journal of Clinical Oncology PathologyTumor BiologyMyeloid NeoplasiaHematological MalignancyOncology	2011	12
Primary pineal tumors – Unraveling histological challenges and certain clinical myths Sridhar Epari, Anuj Verma, David Bakiratharajan, Neurology India	2019	12
A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries Omkara Veeranki, Zhimin Tong, Alicia Mejia, Disease Models & Mechanisms	2019	12

Page 1